Literature DB >> 7713546

Tuberculosis: distribution, risk factors, mortality.

A Kochi1.   

Abstract

About a century after Koch's discovery of the TB bacilli the tuberculosis epidemic which had appeared to be under control was again recognized as a major global health threat. The decline in the epidemic in this century had been largely through the improved living standards and, eventually, the availability and use of effective antibiotics. While tuberculosis gradually disappeared from the health agenda in the western world it remained a big killer throughout the century and in 1992 an estimated 2.7 million TB deaths occurred; 30 million will die from TB during the 1990s if current trends are not reversed. The annual number of new cases will increase from 7.5 million estimated in 1990 to more than 10 million in the year 2000. The main factors for this increase are demographic forces, population movements, the HIV epidemic and increasing drug resistance. The impact of the HIV epidemic is already felt in many sub-Saharan African countries and now threatens Asia where almost two-thirds of the world's TB infected population live and where HIV is spreading. Tuberculosis has also reemerged as a major public health problem in industrialized countries due to international migration, the breakdown of health services, including TB services etc. The control of the epidemic can only be through a concerted action to reinstate TB as priority among health concerns, reflected in national and international resources. A coalition of public and private supporters must be mobilized to support the effort to fight the disease. Governments, non-governmental organizations, the business community, refugee organizations, medical institutions, and other UN agencies are invited to join with WHO in this effort.

Entities:  

Keywords:  Biology; Demographic Factors; Developed Countries; Developing Countries; Diseases; Epidemiology; Health; Incidence; Infections; Measurement; Mortality; Population; Population Dynamics; Public Health; Research Methodology; Risk Factors; Tuberculosis--history

Mesh:

Year:  1994        PMID: 7713546     DOI: 10.1016/S0171-2985(11)80437-7

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  11 in total

1.  Comparison of in vitro models for the study of Mycobacterium tuberculosis invasion and intracellular replication.

Authors:  P K Mehta; C H King; E H White; J J Murtagh; F D Quinn
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

2.  Use of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide for rapid detection of rifampin-resistant Mycobacterium tuberculosis.

Authors:  R N Mshana; G Tadesse; G Abate; H Miörner
Journal:  J Clin Microbiol       Date:  1998-05       Impact factor: 5.948

3.  Reliability of urinary tests for antibody to Helicobacter pylori in patients with pulmonary tuberculosis.

Authors:  Takatsugu Yamamoto; Taro Ishii; Tomotaka Kawakami; Yoko Sase; Chiaki Horikawa; Nozomu Aoki; Masaki Sanaka; Yasushi Kuyama
Journal:  World J Gastroenterol       Date:  2005-01-21       Impact factor: 5.742

4.  Exposure to Latent Tuberculosis Treatment during Pregnancy. The PREVENT TB and the iAdhere Trials.

Authors:  Ruth N Moro; Nigel A Scott; Andrew Vernon; Naomi K Tepper; Stefan V Goldberg; Kevin Schwartzman; Chi-Chiu Leung; Neil W Schluger; Robert W Belknap; Richard E Chaisson; Masahiro Narita; Elizabeth S Machado; Marta Lopez; Jorge Sanchez; Margarita E Villarino; Timothy R Sterling
Journal:  Ann Am Thorac Soc       Date:  2018-05

5.  [Lupus vulgaris manifestation as a destructive nose and facial tumor].

Authors:  D Haller; C Reisser
Journal:  HNO       Date:  2009-04       Impact factor: 1.284

6.  Lay workers in directly observed treatment (DOT) programmes for tuberculosis in high burden settings: Should they be paid? A review of behavioural perspectives.

Authors:  Samson Kironde; Francis Bajunirwe
Journal:  Afr Health Sci       Date:  2002-08       Impact factor: 0.927

7.  Differential influence of nutrient-starved Mycobacterium tuberculosis on adaptive immunity results in progressive tuberculosis disease and pathology.

Authors:  Jes Dietrich; Sugata Roy; Ida Rosenkrands; Thomas Lindenstrøm; Jonathan Filskov; Erik Michael Rasmussen; Joseph Cassidy; Peter Andersen
Journal:  Infect Immun       Date:  2015-09-28       Impact factor: 3.441

8.  Metabolism of the anti-tuberculosis drug ethionamide by mouse and human FMO1, FMO2 and FMO3 and mouse and human lung microsomes.

Authors:  Marilyn C Henderson; Lisbeth K Siddens; Jeffrey T Morré; Sharon K Krueger; David E Williams
Journal:  Toxicol Appl Pharmacol       Date:  2008-10-01       Impact factor: 4.219

9.  HIV and tuberculosis trends in the United States and select Sub-Saharan Africa countries.

Authors:  Ousman Mahmud; Centdrika Dates; Luma Akil; Hafiz A Ahmad
Journal:  Int J Environ Res Public Health       Date:  2011-06-23       Impact factor: 3.390

10.  Heterologous Expression, Purification, and Characterization of the HspX, Ppe44, and EsxV Proteins of Mycobacterium tuberculosis.

Authors:  Yousef Amini; Mohsen Tafaghodi; Saeid Amel Jamehdar; Zahra Meshkat; Bagher Moradi; Mojtaba Sankian
Journal:  Rep Biochem Mol Biol       Date:  2018-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.